QIAGEN N.V./$QGEN
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About QIAGEN N.V.
Qiagen offers proprietary sample and assay technology to extract, purify, amplify, and interpret DNA, RNA, and proteins. The company's sales are split almost evenly between applications in life sciences and molecular diagnostics. Qiagen generates nearly 90% of its revenue from consumables with the balance coming from instrumentation and related services. The Americas account for the largest portion of the firm's revenue (52% of 2024 sales), followed by EMEA (33%), and the Asia-Pacific (15%).
Ticker
$QGEN
Sector
Primary listing
NYSE
Employees
5,654
Headquarters
Website
QIAGEN N.V. Metrics
BasicAdvanced
$8.5B
20.18
$2.04
0.68
$0.26
0.64%
Price and volume
Market cap
$8.5B
Beta
0.68
52-week high
$57.82
52-week low
$40.92
Average daily volume
2.3M
Dividend rate
$0.26
Financial strength
Current ratio
3.896
Quick ratio
2.932
Long term debt to equity
43.789
Total debt to equity
43.789
Dividend payout ratio (TTM)
12.77%
Interest coverage (TTM)
16.62%
Profitability
EBITDA (TTM)
746.356
Gross margin (TTM)
66.37%
Net profit margin (TTM)
20.33%
Operating margin (TTM)
26.44%
Effective tax rate (TTM)
13.34%
Revenue per employee (TTM)
$370,000
Management effectiveness
Return on assets (TTM)
5.76%
Return on equity (TTM)
11.57%
Valuation
Price to earnings (TTM)
20.18
Price to revenue (TTM)
4.1
Price to book
2.25
Price to tangible book (TTM)
12.29
Price to free cash flow (TTM)
19.162
Free cash flow yield (TTM)
5.22%
Free cash flow per share (TTM)
2.151
Dividend yield (TTM)
0.64%
Forward dividend yield
0.64%
Growth
Revenue change (TTM)
5.65%
Earnings per share change (TTM)
409.76%
3-year revenue growth (CAGR)
-0.81%
10-year revenue growth (CAGR)
5.02%
3-year earnings per share growth (CAGR)
-0.19%
10-year earnings per share growth (CAGR)
12.35%
QIAGEN N.V. News
AllArticlesVideos
QIAGEN Receives U.S. Clearance for Gastrointestinal Panels on Fully Automated QIAstat-Dx Rise Syndromic Testing System
Business Wire·1 day ago
Parse Biosciences Launches Evercode Whole Transcriptome V4 With Shorter Workflow, Higher Sensitivity and Higher Cell Recovery
Business Wire·3 weeks ago
QIAGEN Showcases QIAsprint Connect High-Throughput Automation System for Labs Worldwide at SLAS 2026
Business Wire·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for QIAGEN N.V. stock?
QIAGEN N.V. (QGEN) has a market cap of $8.5B as of March 12, 2026.
What is the P/E ratio for QIAGEN N.V. stock?
The price to earnings (P/E) ratio for QIAGEN N.V. (QGEN) stock is 20.18 as of March 12, 2026.
Does QIAGEN N.V. stock pay dividends?
Yes, the QIAGEN N.V. (QGEN) stock pays dividends to shareholders. As of March 12, 2026, the dividend rate is $0.26315 and the yield is 0.64%. QIAGEN N.V. has a payout ratio of 12.77% on a trailing twelve-month basis.
When is the next QIAGEN N.V. dividend payment date?
The next QIAGEN N.V. (QGEN) dividend payment date is unconfirmed.
What is the beta indicator for QIAGEN N.V.?
QIAGEN N.V. (QGEN) has a beta rating of 0.68. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.